Poly-DNP-RNA-21

The RIa/PKA gene is often overexpressed in cancers of the breast, lung, colon, prostate and ovary. UB researchers have synthesized a new compound, DNP-ssRNA-21, that triggers cleavage of the mRNA of RIa/PKA, thereby leading to growth inhibition and apoptosis of these cancer cells but with no effect on normal cell lines without RIa/PKA gene overexpression.

Compared to GEM 231, an antisense therapeutic currently in Phase I/II clinical trials, DNP-ssRNA-21 is 30- to 900-fold more potent in vi tro. High in vitro binding affinity, efficacy and specificity suggest that DNP-ssRNA-21 could be developed as a promising anticancer agent. Other advantageous features of the technology include easier delivery, stability in the presence of RNases , and stereochemical homogeneity, all of which should be valuable for future therapeutic applications.

Categories: Genomics, Therapeutic and Vaccines

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---